Daily FNArena News

T Rowe Price says breaking away from reliance on traditional approaches and exploring new growth drivers can help investors to capture some of the many new investment opportunities emerging in Chinese stocks

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Is copper too exhibiting over-excited investor optimism?

A lack of junior miner exploration in tough economic times has weighed on drill supplier Imdex, but brokers believe an upswing is not too far off

Independent Investment Research updates developments in Australia’s listed investment trust and provides comparative data

Tony Sycamore, Market Analyst, IG updated his technical views on the Nasdaq, the ASX200, and crude oil (WTI)

Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports

The Australian market couldn’t sustain the early May rally, weighed down by a surprisingly high April CPI reading and some negative earnings updates

RBC Capital Markets sees further market share gains ahead for specialist wealth management platforms Netwealth, Hub24 and Praemium